-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $110

Benzinga·03/26/2026 15:08:33
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $100 to $110.